Patents by Inventor Jonathan Gareth Williams
Jonathan Gareth Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10358445Abstract: The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).Type: GrantFiled: December 5, 2014Date of Patent: July 23, 2019Assignee: RESPIVERT, LTD.Inventors: Peter John Murray, Stuart Thomas Onions, Jonathan Gareth Williams, Kevin Joly
-
Patent number: 10144721Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.Type: GrantFiled: January 6, 2016Date of Patent: December 4, 2018Assignee: Respivert Ltd.Inventors: John King-Underwood, Ito Kazuhiro, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Publication number: 20180201611Abstract: The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).Type: ApplicationFiled: December 5, 2014Publication date: July 19, 2018Inventors: Peter John Murray, Stuart Thomas Onions, Jonathan Gareth Williams, Kevin Joly
-
Patent number: 10000471Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.Type: GrantFiled: August 29, 2017Date of Patent: June 19, 2018Assignee: Respivert LimitedInventors: John King-Underwood, George Hardy, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Publication number: 20170362208Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.Type: ApplicationFiled: August 29, 2017Publication date: December 21, 2017Applicant: Respivert LimitedInventors: John King-Underwood, George Hardy, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Patent number: 9771354Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.Type: GrantFiled: January 18, 2016Date of Patent: September 26, 2017Assignee: Respivert Ltd.Inventors: John King-Underwood, George Hardy, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Patent number: 9701670Abstract: There are provided compounds of formula I, wherein R, R1, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 16, 2013Date of Patent: July 11, 2017Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITEDInventors: Claire Anne Marie Cariou, Catherine Elisabeth Charron, Euan Alexander Fraser Fordyce, Daniel Hamza, Matthew Colin Thor Fyfe, Kazuhiro Ito, John King-Underwood, Peter John Murray, Stuart Thomas Onions, Stephen Malcolm Thom, Hayley Tegan Angela Watson, Jonathan Gareth Williams
-
Publication number: 20160130256Abstract: There are provided inter alia compounds of formula (I) wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.Type: ApplicationFiled: January 18, 2016Publication date: May 12, 2016Applicant: Respivert LimitedInventors: John King-Underwood, George Hardy, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Publication number: 20160115152Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.Type: ApplicationFiled: January 6, 2016Publication date: April 28, 2016Applicant: Respivert Ltd.Inventors: John King-Underwood, Ito Kazuhiro, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Patent number: 9260410Abstract: There is provided inter alia a compound of formula (I): wherein R1, J, Ar, L, X, R3 and R4 are as defined in the specification, for use in the treatment of inflammatory disorders.Type: GrantFiled: April 8, 2011Date of Patent: February 16, 2016Assignee: Respivert Ltd.Inventors: John King-Underwood, Kazuhiro Ito, Peter Strong, William Garth Rapeport, Catherine Elisabeth Charron, Peter John Murray, Jonathan Gareth Williams, Stuart Thomas Onions
-
Patent number: 9249125Abstract: Compounds of formula (I): wherein R1, R2, J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.Type: GrantFiled: August 28, 2013Date of Patent: February 2, 2016Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITEDInventors: Lorna Anne Duffy, John King-Underwood, Alistair Ian Longshaw, Peter John Murray, Stuart Thomas Onions, David Michael Adrien Taddei, Jonathan Gareth Williams, Kazuhiro Ito, Catherine Elisabeth Charron
-
Patent number: 9242960Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.Type: GrantFiled: February 3, 2014Date of Patent: January 26, 2016Assignee: Respivert, Ltd.Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Onions, Catherine Elisabeth Charron
-
Publication number: 20150218137Abstract: There are provided compounds of formula I, wherein R, R1, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: August 16, 2013Publication date: August 6, 2015Inventors: Claire Anne Marie Cariou, Catherine Elisabeth Charron, Euan Alexander Fraser Fordyce, Daniel Hamza, Matthew Colin Thor Fyfe, Kazuhiro Ito, John King-Underwood, Peter John Murray, Stuart Thomas Onions, Stephen Malcolm Thom, Hayley Tegan Angela Watson, Jonathan Gareth Williams
-
Publication number: 20150203475Abstract: Compounds of formula (I): wherein R1, R2, J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.Type: ApplicationFiled: August 28, 2013Publication date: July 23, 2015Applicant: TOPIVERT PHARMA LIMITEDInventors: Lorna Anne Duffy, John King-Underwood, Alistair Ian Longshaw, Peter John Murray, Stuart Thomas Onions, David Michael Adrien Taddei, Jonathan Gareth Williams, Kazuhiro Ito, Catherine Elisabeth Charron
-
Patent number: 9024041Abstract: There is provided a compound of formula (I): wherein: J represents (A): or (B): compositions comprising same, processes for preparing said compounds and use thereof in treatment, particularly in the treatment of inflammatory disease, such as asthma, COPD and 15 rheumatoid arthritis.Type: GrantFiled: April 8, 2011Date of Patent: May 5, 2015Assignee: Respivert Ltd.Inventors: John King-Underwood, Peter John Murray, Jonathan Gareth Williams, Ildiko Buck, Stuart Thomas Onions
-
Patent number: 8975285Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.Type: GrantFiled: December 24, 2013Date of Patent: March 10, 2015Assignee: Respivert Ltd.Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
-
Patent number: 8933228Abstract: The present invention relates to respiratory formulations comprising a compound of formula (I): and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).Type: GrantFiled: June 17, 2011Date of Patent: January 13, 2015Assignee: Respivert, Ltd.Inventors: Peter John Murray, Stuart Thomas Onions, Jonathan Gareth Williams, Kevin Joly
-
Publication number: 20140228410Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.Type: ApplicationFiled: February 3, 2014Publication date: August 14, 2014Applicant: Respivert Ltd.Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart ONIONS, Catherine Elisabeth Charron
-
Publication number: 20140114064Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.Type: ApplicationFiled: December 24, 2013Publication date: April 24, 2014Applicant: Respivert Ltd.Inventors: Kazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart Thomas Onions, Simon Christopher Hirst, David Michel Adrien Taddei, Catherine Elisabeth Charron
-
Publication number: 20140057915Abstract: There are provided compounds of formula I, wherein R, R1, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: ApplicationFiled: August 16, 2013Publication date: February 27, 2014Applicants: TOPIVERT PHARMA LIMITED, RESPIVERT LIMITEDInventors: CLAIRE ANNE MARIE CARIOU, CATHERINE ELISABETH CHARRON, EUAN ALEXANDER FRASER FORDYCE, MATTHEW COLIN THOR FYFE, DANIEL HAMZA, KAZUHIRO ITO, JOHN KING-UNDERWOOD, PETER JOHN MURRAY, STUART THOMAS ONIONS, STEPHEN MALCOLM THOM, HAYLEY TEGAN ANGELA WATSON, JONATHAN GARETH WILLIAMS